Diabetic Foot Ulcers
4
Pipeline Programs
3
Companies
4
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 2 programs with unclassified modality
On Market (1)
Approved therapies currently available
U
OFLOXACINApproved
ofloxacin
Unknown Companyophthalmic2024
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Abeona TherapeuticsCLEVELAND, OH
2 programs2
ofloxacinPhase 3Small Molecule1 trial
ofloxacinPhase 3Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Abeona Therapeuticsofloxacin
Abeona Therapeuticsofloxacin
Karyopharm TherapeuticsSelinexor
OrganogenesisAffinity Allograft
Clinical Trials (4)
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Start: Aug 1994Est. completion: Jul 1996
Phase 3Completed
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Start: Aug 1994Est. completion: Jul 1996
Phase 3Completed
Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients
Start: Jan 2015Est. completion: Sep 2015
Phase 1/2Withdrawn
Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers
Start: Aug 2016Est. completion: Apr 2019
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space